陈万青，1971年生，籍贯天津，永利集团3044官网欢迎您肿瘤医院研究员，博士生导师。1995年毕业于白求恩医科大学临床医学系，2004年获澳大利亚悉尼大学公共卫生学院国际公共卫生荣誉硕士学位，2014年获悉尼大学Ph.D学位。1995年于永利集团3044官网欢迎您肿瘤医院放射治疗科从事临床工作5年，2005年回国后留任永利集团3044官网欢迎您肿瘤医院全国肿瘤防治研究办公室副主任，2018年任癌症早诊早治办公室主任，负责多项国家重大公共卫生项目。2016年晋升为研究员，2018年获博士研究生导师资格。

研究方向为肿瘤流行病学，重点研究方向包括：我国常见癌症筛查干预方案的流行病学和卫生经济学评价研究，癌症疾病负担和经济负担研究。

1. Li N#, Tan F#, Chen W#, Dai M#, Wang F, Shen S, Tang W, Li J, Yu Y, Cao W, Xu Y, Qin C, Zhao L, Zhu M, Guo L, Wu Z, Yang Z, Zheng Y, Chen H, Liu Y, Wei D, Dong D, Cao J, Zhang S, Yan S, Wang N, Du L, Shen H, Wu N, He J. One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study. Lancet Respir Med. 2022, 10(4):378-91. (IF=102.642)

2. Xia R#, Li H#, Shi J#, Liu W, Cao M, Sun D, He S, Yu Y, Li N, Lei L, Zhuang G*, Chen W*. Cost-effectiveness of risk-stratified endoscopic screening for esophageal cancer in high-risk areas of China: a modeling study. Gastrointest Endosc. 2022, 95(2):225-35.e20. (IF=10.396)

3. Li H#, Ding C#, Zeng H, Zheng R, Cao M, Ren J, Shi J, Sun D, He S, Yang Z, Yu Y, Zhang Z, Sun X, Guo G, Song G, Wei W, Chen W*, He J*. Improved esophageal squamous cell carcinoma screening effectiveness by risk-stratified endoscopic screening: evidence from high-risk areas in China. Cancer Commun (Lond). 2021, 41(8):715-725. (IF=10.392)

4. Chen W#*, Xia C#, Zheng R, Zhou M, Lin C, Zeng H, Zhang S, Wang L, Yang Z, Sun K, Li H, Brown MD, Islami F, Bray F, Jemal A, He J*. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Glob Health. 2019, 7(2):e257-69. (IF=21.597, C100, ESI)

5. Zeng H#, Chen W*, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J*. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018, 6(5):e555-67. (IF=15.873, C100, ESI, R)

6. Chen W#*, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J*. Cancer incidence and mortality in China, 2013. Cancer Let. 2017, 401:63-71. (IF=6.491, C100, ESI)

7. Islami F#*, Chen W*, Yu XQ, Lortet-Tieulent J, Zheng R, Flanders WD, Xia C, Thun MJ, Gapstur SM, Ezzati M, Jemal A. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol. 2017, 28(10):2567-74. (IF=11.855, C100, ESI)

8. Chen W#*, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J*. Cancer statistics in China, 2015. CA Cancer J Clin. 2016, 66(2):115-32. (IF=187.04, C100, ESI)

9. Zhou M#, Wang H#, Zhu J#, Chen W#, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P, Liu J, Yu S, Tan F, Barber RM, Coates MM, Dicker D, Fraser M, González-Medina D, Hamavid H, Hao Y, Hu G, Jiang G, Kan H, Lopez AD, Phillips MR, She J, Vos T, Wan X, Xu G, Yan LL, Yu C, Zhao Y, Zheng Y, Zou X, Naghavi M, Wang Y*, Murray CJ*, Yang G*, Liang X*. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016, 387(10015):251-72. (IF= 47.831, C100, ESI)

10. Zeng H#, Zheng R#, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, Huang S, Wang J, Yu L, Zhao D, Song G, Chen J, Shen Y, Yang X, Gu X, Jin F, Li Q, Li Y, Ge H, Zhu F, Dong J, Guo G, Wu M, Du L, Sun X, He Y, Coleman MP, Baade P, Chen W*, Yu XQ. Cancer survival in China, 2003-2005: a population-based study. Int J Cancer. 2015, 136(8):1921-30. (IF=6.513, C100, ESI)